Antibody Drug Conjugate (ADC) Manufacturing - Embrace the Future: It’s Happening Now.
ADCs are an advanced cancer therapy designed to precisely target and deliver cytotoxic agents directly to cancer cells.
ILC Dover is the global leader in high-containment systems for handling potent pharmaceutical ingredients. Since 1997, we’ve pioneered single-use isolator technology that lowers capital and operating costs while delivering proven containment performance. Designed for highly potent APIs, including the most powerful toxin linkers, our systems consistently achieve below 1.0 nanogram / m3 airborne concentration containment limit, verified through ISPE SMEPAC testing and SafeBridge Consultants analysis. With no cleaning or filter changes required, the fully disposable design allows safe disposal and faster changeover, getting production running again in hours, not days.
ILC Dover has developed technology for containment across the ADC workflow. The innovative designs protect operators and the environment, leveraging single-use systems that reduce risks of contamination and costs associated with cleaning stainless steel components. This improves production efficiency to when cleaning is eliminated, and the equipment is available quickly.
Let ILC Dover be your trusted partner in ADC Manufacturing —where quality, flexibility, and innovation come together.




.jpg?format=pjpeg&width=100&quality=10)




